A Comparison of Reboxetine and Amitryptilline in the Treatment of Fibromyalgia Syndrome with Co-morbid Depressive Symptoms: An Open-label Preliminary Study

Konuk, Numan; Ortancil, Özgür; Bostanci, Bora; Kıran, Sibel; Sapmaz, Perihan

doi:10.1080/10177833.2010.11790631

Cited by 8 publications

(3 citation statements)

References 42 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study by Sumpton and Moulin [2], the authors found that tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors (SNRIs) (duloxetine and milnacipran), and α2-δ ligands (gabapentin and pregabalin) are effective in reducing FM-associated pain by ≥30%. Amitriptyline was also associated with improvement in pain fatigue, sleep, and quality of life [50][51][52].…”

Section: Pharmacological Treatmentmentioning

confidence: 98%

Review of Fibromyalgia (FM) Syndrome Treatments

Cohen-Biton

Buskila

Nissanholtz-Gannot

2022

IJERPH

View full text Add to dashboard Cite

Background: Fibromyalgia (FM) is a disease characterized by widespread musculoskeletal chronic pain that impairs the patient’s quality of life and is considered a somatization disorder. The symptoms of the disease also affect the patient mentally, mainly since invisible pain is the only thing that indicates its existence. A typical symptom that characterizes FM patients is the lack of acceptance of the disease since its pathophysiology is not elucidated, hence the deficiencies in its management, or rather, cognitively, the belief that there is no disease to manage. The current paper aims to shed light on the new treatment methods at a holistic level, that is, cognitive, physical, and pharmacological therapies. Method: A literature review was carried out that discusses treatment methods that help alleviate the pain, accept it, and manage the symptoms of the disease. Results: FM symptoms can be treated by taking a broad view of treatment that will include a response to the mind through pain management, response to the body through physical activity, and response to the pain through pharmacological treatment. Conclusions: Today, there is an evolutionary view that accepts FM and chronic pain diseases as syndromes in which the pain is the disease; therefore, the response to this disease can be applied through three channels: physical, bodily, and mental.

show abstract

Section: Pharmacological Treatmentmentioning

confidence: 98%

Review of Fibromyalgia (FM) Syndrome Treatments

Cohen-Biton

Buskila

Nissanholtz-Gannot

2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…Amitriptyline was found to reduce the FIQ questionnaire results from baseline to endpoint by over 30% [48][49][50]. It was found to improve pain, fatigue, sleep, and quality of life [11].…”

Section: Tricyclic Antidepressants (Tcas) Although Differentmentioning

confidence: 99%

Current and Emerging Pharmacotherapy for Fibromyalgia

Tzadok

Ablin

2020

Pain Research and Management

View full text Add to dashboard Cite

Introduction. Fibromyalgia syndrome (FMS) is a pain disorder with an estimated prevalence of 1–5%. It is associated with a variety of somatic and psychological disorders. Its exact pathogenesis is still unclear but is involved with neural oversensitization and decreased conditioned pain modulation (CPM), combined with cognitive dysfunction, memory impairment, and altered information processing. Connectivity between brain areas involved in pain processing, alertness, and cognition is increased in the syndrome, making its pharmacologic therapy complex. Only three drugs, pregabalin, duloxetine, and milnacipran are currently FDA-approved for FM treatment, but many other agents have been tested over the years, with varying efficacy. Areas Covered. The purpose of this review is to summarize current clinical experience with different pharmacologic treatments used for fibromyalgia and introduce future perspectives in developing therapies. Expert Opinion. Future insights into the fields of cannabinoid and opioid research, as well as an integrative approach towards the incorporation of genetics and functional imaging combined with additional fields of research relevant towards the study of complex CNS disorders, are likely to lead to new developments of novel tailor-made treatments for FMS patients.

show abstract

“…Although action at muscarinic and histamine receptors of antidepressants has been related to the adverse cardiotoxicity and gastrointestinal disturbance, and sedative properties respectively, antinociceptive effects may also be achieved by actions at these receptors [ 27 , 28 ]. The efficacy of antidepressant drugs tested as treatments of fibromyalgia on the characteristic symptoms and quality of life assessments are summarized in Table 2 [ 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 ].…”

Section: Pharmacology Of Antidepressants and Fibromyalgiamentioning

confidence: 99%

A Brief Review of the Pharmacology of Amitriptyline and Clinical Outcomes in Treating Fibromyalgia

Lawson

2017

Biomedicines

View full text Add to dashboard Cite

Fibromyalgia is a complex chronic condition characterized by pain, physical fatigue, sleep disorder and cognitive impairment. Evidence-based guidelines recommend antidepressants as treatments of fibromyalgia where tricyclics are often considered to have the greatest efficacy, with amitriptyline often being a first-line treatment. Amitriptyline evokes a preferential reduction in pain and fatigue of fibromyalgia, and in the Fibromyalgia Impact Questionnaire (FIQ) score, which is a quality of life assessment. The multimodal profile of the mechanisms of action of amitriptyline include monoamine reuptake inhibition, receptor modulation and ion channel modulation. Several of the actions of amitriptyline on multiple nociceptive and sensory processes at central and peripheral locations have the potential to act cumulatively to suppress the characteristic symptoms of fibromyalgia. Greater understanding of the role of these mechanisms of action of amitriptyline could provide further clues to the pathophysiology of fibromyalgia and to a preferable pharmacological profile for future drug development.

show abstract

A Comparison of Reboxetine and Amitryptilline in the Treatment of Fibromyalgia Syndrome with Co-morbid Depressive Symptoms: An Open-label Preliminary Study

Cited by 8 publications

References 42 publications

Review of Fibromyalgia (FM) Syndrome Treatments

Review of Fibromyalgia (FM) Syndrome Treatments

Current and Emerging Pharmacotherapy for Fibromyalgia

A Brief Review of the Pharmacology of Amitriptyline and Clinical Outcomes in Treating Fibromyalgia

Contact Info

Product

Resources

About